Results 31 to 40 of about 2,144 (203)

Omadacycline [PDF]

Hospital Pharmacy, 2019
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
openaire   +2 more sources

Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media [PDF]

, 2017
Pharmacodynamic properties of marbofloxacin were established for six isolates each of the pig respiratory tract pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey, L, Hobson, S, Lees, P
core   +2 more sources

Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility

Microbiology Spectrum, 2022
Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent in vitro activity, synergism with other agents, and acceptable toxicity profile.
Taylor Abbey, Alesia Vialichka, Michele Jurkovic, Mark Biagi, Eric Wenzler   +4 more
doaj   +1 more source

Microbiology and Preclinical Review of Omadacycline [PDF]

Clinical Infectious Diseases, 2019
AbstractOmadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, vancomycin-resistant Enterococcus,
Karlowsky, James A, Steenbergen, Judith, Zhanel, George G   +2 more
openaire   +2 more sources

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective [PDF]

, 2017
To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-
Harbarth, S., Macedo-Vinas, M., Morel, C. M., Murthy, A., Olearo, F., Pagani, L., von Dach, E.   +6 more
core   +2 more sources

Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump

SAGE Open Medicine, 2022
Objective: To investigate compatibility, stability, and microbiologic risk of omadacycline 1 mg/mL when prepared in an elastomeric infusion pump and stored under refrigeration for 9 days based upon requests for information from healthcare providers ...
Jason Bower, Kelly Wright, Jason Burdette   +2 more
doaj   +1 more source

Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms

BioMed Research International, Volume 2023, Issue 1, 2023., 2023
Antimicrobial resistance (AMR) is a ubiquitous public health menace. AMR emergence causes complications in treating infections contributing to an upsurge in the mortality rate. The epidemic of AMR in sync with a high utilization rate of antimicrobial drugs signifies an alarming situation for the fleet recovery of both animals and humans.
Sarfraz Ahmed, Muhammad Zeeshan Ahmed, Safa Rafique, Seham Eid Almasoudi, Mohibullah Shah, Nur Asyilla Che Jalil, Suvash Chandra Ojha, Mahmoud Kandeel   +7 more
wiley   +1 more source

Clinically Approved Antibiotics from 2010 to 2022 [PDF]

, 2023
This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives ...
Gademann, Karl, Jung, Erik
core   +1 more source

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates

Antibiotics, 2022
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management ...
Manas S. Deolankar, Rachel A. Carr, Rebecca Fliorent, Sean Roh, Henry Fraimow, Valerie J. Carabetta   +5 more
doaj   +1 more source

Meeting the Unmet Need in the Management of MDR Gram‐Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Critical Care Research and Practice, Volume 2022, Issue 1, 2022., 2022
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad‐spectrum antibacterial agents developed for the treatment of difficult‐to‐treat infections caused by multidrug‐resistant Gram‐positive bacteria, especially methicillin‐resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well
Yatin Mehta, K. C. Mishra, Yashesh Paliwal, Pradeep Rangappa, Sharmili Sinha, Sandeep Bhapkar, Guowei Tu   +6 more
wiley   +1 more source